Talecris deal could be delayed, UBS says - Triangle Business Journal:

grigoriynirim.blogspot.com
Talecris, based in Research Triangle Park, agreed in 2008 to be purchaseddby Australia’s for $3.1 billion in stock and Both companies make therapiesw from human plasma found in the blood. The deal is a big one for which currently is owned by investment firms Cerberus Capitao Management andAmpersand Ventures, and the company’ds more than 2,000 Triangle workers. Most analystzs agree that Talecris would be made stronger after comingunder CSL’s umbrella. But the which would combine the world’s No. 2 and No. 3 produceras of plasma drugs, . In October, the U.S. Federall Trade Commission asked CSL for more information aboutthe merger. In a Jan.
19 CSL says it expects to responc tothe FTC’s request in a matterf of days. The FTC is “administrativelgy bound” to respond to CSL in 30 but the anti-trust review could take much analyst AndrewGoodsall writes. If the Talecris-CSL deal isn’ty done by August, CSL would owe Talecris’ current owners $75 The deal’s failure also would muddh the futurefor Talecris, which already had triex to go public before it agreed to the CSL deal. A CSL spokespersonh wasn’t immediately available for comment.